LP-184

Lantern Pharma has established Open Medicine AI as a separate company to commercialize and expand its multi-agent AI co-scientist platform, moving a previously planned separation into an active corporate structure. The decision could give the artificial intelligence business greater strategic focus and access to specialized funding, but ownership, intellectual property, customer revenue and future listing arrangements will determine whether the move creates measurable value for Lantern Pharma shareholders.